Outcomes of Irreversible Electroporation for Perihilar Cholangiocarcinoma: A Prospective Pilot Study

• Published in: Journal of vascular and interventional radiology Vol. 33; no. 7; pp. 805 - 813.e1
• Main Authors: Franken, Lotte C., van Veldhuisen, Eran, Ruarus, Alette H., Coelen, Robert J.S., Roos, Eva, van Delden, Otto M., Besselink, Marc G., Klümpen, Heinz-Josef, van Lienden, Krijn P., van Gulik, Thomas M., Meijerink, Martijn R., Erdmann, Joris I.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022
• Subjects: CT; PHC; PTBD; OS; IRE; CI
• ISSN: 1051-0443; 1535-7732
• DOI: 10.1016/j.jvir.2022.03.024

To investigate the safety and efficacy of percutaneous or open irreversible electroporation (IRE) in a prospective cohort of patients with locally advanced, unresectable perihilar cholangiocarcinoma (PHC). In a multicenter Phase I/II study, patients with unresectable PHC due to extensive vascular involvement or N2 lymph node metastases or local recurrence after resection for PHC were included and treated by open or percutaneous IRE combined with palliative chemotherapy (current standard of care). The primary outcome was the number of major adverse events occurring within 90 d after IRE (grade ≥3), and the upper limit was predefined at 60%. Secondary outcomes included technical success rate, hospital stay, and overall survival (OS). Twelve patients (mean age, 63 y ± 12) were treated with IRE. The major adverse event rate was 50% (6 of 12 patients), and no 90-d mortality was observed. All procedures were technically successful, with no intraprocedural adverse events requiring additional interventions. The median OS from diagnosis was 21 mos (95% confidence interval, 15–27 mos), with a 1-y survival rate of 75% after IRE. Percutaneous IRE in selected patients with locally advanced PHC seems feasible, with a major adverse event rate of 50%, which was below the predefined upper safety limit in this prospective study. Future comparative research exploring the efficacy of IRE is warranted.